Interest in taking GLP-1 medication at less than the standard dose has grown quickly, and the pages that rank for it tend to publish dose schedules. This page does not. Your dose is a decision for you and your prescriber, and the evidence base here is thinner than most articles admit. What follows is what the practice means, why people do it, and what the research does and does not support. It is educational only and not medical advice.
"Microdosing" is not a regulatory or clinical term, which is part of why the conversation is muddled. In common use it means staying below the labeled maintenance dose long-term, rather than titrating up to the standard target the way the prescribing information describes. Some people use it to mean a slower climb; others mean settling permanently at a fraction of the usual dose.
Because it is not a defined protocol, two people describing themselves as microdosing may be doing quite different things. That matters when you read anecdotes.
Four reasons come up consistently, and they are not equally weighted for everyone:
These are understandable reasons. None of them is the same as evidence that a lower dose works as well.
Here is the honest position: there is no randomized controlled trial testing microdosing as a strategy. No study has compared a deliberately sub-label maintenance dose against the standard dose and reported how much of the benefit is retained for how much of the cost. What exists is clinician practice — some prescribers do use lower-than-label doses for specific patients and specific reasons — and a large volume of self-reported experience online.
The more defensible summary: GLP-1 medications show a dose–response relationship, meaning higher doses generally produce more weight loss on average, but the curve is not a straight line and individuals vary considerably. Some people do get meaningful results below the target dose. Whether you would is not something an article can tell you.
This is where we differ from most pages on this topic, deliberately.
If a lower dose is something you want to explore, it is a reasonable conversation to have — with the person who can actually assess it. Useful questions:
Pepathary will not suggest a dose, calculate one for you, or recommend microdosing. What it does is record the plan your prescriber set: doses and timing, a side-effect log, weight and measurements over time, and an export you can hand to your doctor. If you and your physician do decide to try something different, having a clear before-and-after record is what makes that conversation useful rather than anecdotal.
It is an informal term, not a clinical or regulatory one. In general use it means staying below the labeled maintenance dose long-term rather than titrating up to the standard target described in the prescribing information. Because it is not a defined protocol, two people who say they are microdosing may be doing quite different things, which is worth remembering when reading anecdotes.
There is no randomized controlled trial testing microdosing as a strategy. No study has compared a deliberately sub-label maintenance dose against a standard dose to measure how much benefit is retained. What exists is clinician practice in specific cases and a large amount of self-reported experience online. GLP-1 medications do show a dose-response relationship, so lower doses generally produce less average weight loss, though individuals vary.
No, and this is a widely repeated error. One milligram of semaglutide is a standard therapeutic dose on the normal titration ladder, not a microdose. Citing weight loss at 1 mg as proof that microdosing works compares one regular dose against a higher regular dose. It tells you something about the shape of the dose-response curve, but nothing about whether a small fraction of a maintenance dose preserves the benefit.
No. The labeled dosing schedules are what the medications were studied and approved with. Prescribing below them is off-label, which a physician may legally do based on clinical judgment for an individual patient, but it is not an approved regimen and it is not something to improvise on your own.
That is a decision to make with your prescriber rather than alone. Beyond the clinical question, drawing a smaller amount than a device was designed to deliver introduces measurement error, and confusion between units and milligrams is a documented cause of serious dosing mistakes with these medications. If the product is compounded, the actual concentration may also differ from the label, so careful arithmetic on an uncertain starting number is still uncertain.
Ask what you are being treated for and whether that changes how much room there is to go lower; whether a slower titration would address side effects instead of a lower ceiling; whether coverage, savings programs or formulary options could address cost; what maintenance should look like for you if you have reached your goal; and how you would both monitor whether a lower dose is still working.